Abstract Number: 0265 • ACR Convergence 2022
In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
Background/Purpose: Disease activity scores like CDAI, SDAI, or DAS28, are essential for measuring rheumatoid arthritis (RA) disease activity. These scores do not contain foot joints.…Abstract Number: 0283 • ACR Convergence 2022
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…Abstract Number: 0299 • ACR Convergence 2022
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…Abstract Number: 0398 • ACR Convergence 2022
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…Abstract Number: 0558 • ACR Convergence 2022
Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation
Background/Purpose: mTOR is a metabolic master regulator of both innate and adaptive immunity, however its exact role in synovial fibroblasts is unknown. RA synovial fibroblasts…Abstract Number: 0597 • ACR Convergence 2022
TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: TNF-α is a proinflammatory cytokine in rheumatoid arthritis that exerts effect through specific receptors TNFR1/2. Though it is a primary therapeutic target, there exist…Abstract Number: 0615 • ACR Convergence 2022
Semaphorin 5A Suppresses Ferroptosis Through Activation of PI3K-AKT-mTOR Signaling in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…Abstract Number: 0711 • ACR Convergence 2022
Improvement in Excess Mortality in Patients with Rheumatoid Arthritis over the Last Two Decades: A Danish Population-based Matched Cohort Study
Background/Purpose: Results from previous studies investigating mortality trends in patients with rheumatoid arthritis (RA) have been inconsistent, most likely due to varying cohort sizes and…Abstract Number: 0774 • ACR Convergence 2022
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Background/Purpose: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been…Abstract Number: 0887 • ACR Convergence 2022
Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database
Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…Abstract Number: 0903 • ACR Convergence 2022
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…Abstract Number: 0919 • ACR Convergence 2022
Predictors of Methotrexate Monotherapy Response in Patients with Active Rheumatoid Arthritis: Results from a Multicentre, Randomized Controlled Trial
Background/Purpose: Methotrexate (MTX) is the gold standard, first-line therapy for rheumatoid arthritis (RA). However, not all patients respond to MTX, and the predictors of its…Abstract Number: 0936 • ACR Convergence 2022
Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial
Background/Purpose: Methotrexate (MTX) significantly decreases the vaccine response to pneumococcal and seasonal influenza vaccines and temporarily discontinuing MTX for 2 weeks in patients with rheumatoid…Abstract Number: 1146 • ACR Convergence 2022
Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) genetic susceptibility has been well studied with five amino acid positions within the HLA explaining most of the association. Although genome…Abstract Number: 1261 • ACR Convergence 2022
Scoring Structural Damage in Rheumatoid Arthritis by Ultrasound: Results from a Delphi Process and Web-Based Reliability Exercise by the OMERACT Ultrasound Working Group
Background/Purpose: Structural damage in rheumatoid arthritis (RA) includes bone erosions, cartilage changes, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown…
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 219
- Next Page »
